drugset / Trial / NCT04425564

Study of Metronomic Capecitabine and Oxaliplatin Versus XELOX in Egyptian Metastatic Colorectal Cancer Patients

NCT04425564 ↗

Phase 2 Completed 70 enrolled National Cancer Institute, Egypt
RandomizedParallel-groupOpen-labelOther

Summary

Colorectal cancer (CRC) in Egypt is advanced tumors at diagnosis. Although, the dramatic increase in efficacy, reduction of mortality, and improvements in survival by the use of standard doses of chemotherapy, some CRC patients suffer from severe toxicities besides disease progression. Use of chemotherapy less than the maximum tolerated dose, with no prolonged drug free breaks incapacitates the cells to engage in progression mechanisms, suggesting that it could be a better alternative to standard dose therapy with better toxicity profile

Timeline

Start
2016-01-01
Primary completion
2017-06-30
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1000 mg/m2 —
Subject Capecitabine Small molecule 2000 mg —
Subject Oxaliplatin Small molecule 30 mg/m2 —
Subject Oxaliplatin Small molecule 130 mg/m2 —

Indications